Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 8/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.39 |
| ▸ | PTPRB | P23467 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4958080 | 0.85 | PTPN1 (0.45) | PTPN5PTPN1PTPN2PTPRBPTPN6 | |
| SCHEMBL4957299 | 0.85 | PTPN1 (0.39) | PTPN5PTPN1GCGRNPC1LMNA | |
| SCHEMBL4959788 | 0.83 | PTPN1 (0.38) | PTPN1PTPN2NPC1LMNAHPGD | |
| SCHEMBL6153971 | 0.83 | S1PR1 (0.40) | NPC1LMNAHPGDHSD17B10 | |
| SCHEMBL4955542 | 0.83 | KMO (0.38) | PTPN5NPC1LMNAHPGDHSD17B10 | |
| SCHEMBL4957207 | 0.82 | KMO (0.36) | PTPN5PTPN1GCGRNPC1LMNA | |
| SCHEMBL4955510 | 0.82 | NR1H2 (0.38) | PTPN5PTPN1NPC1LMNAHPGD | |
| SCHEMBL6678797 | 0.82 | GCGR (0.35) | GCGRNPC1LMNAHPGDHSD17B10 | |
| SCHEMBL6154252 | 0.81 | GCGR (0.39) | PTPN1GCGRNPC1LMNAHPGD | |
| SCHEMBL6678801 | 0.81 | HSD17B10 (0.35) | GCGRNPC1LMNAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2005-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | PTPRS, PTPRJ, PTPRCAP | PTPN5 14/4885PTPN1 15/4885PTPN2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.